American Society of Hirudotherapy

Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)

Investigational adjunct in NAFLD/MASLD; no human clinical study identified; weight loss, dietary modification, and resmetirom remain primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for non-alcoholic fatty liver disease (NAFLD/MASLD). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for NAFLD is investigational.
What evidence exists?
Tier C (investigational). No human clinical study of leech therapy for fatty liver was identified; only a few animal studies exist. Evidence-based management of NAFLD/MASLD per AASLD guidelines: weight loss 7-10 percent (most effective intervention), Mediterranean diet, reduction of fructose and alcohol intake, treatment of metabolic comorbidities (diabetes, dyslipidemia), GLP-1 receptor agonists (semaglutide, tirzepatide) for weight loss and hepatic benefit, resmetirom (newly FDA-approved for MASH with fibrosis stages F2-F3). Vitamin E in selected non-diabetics with MASH. Bariatric surgery in eligible obese patients.
Main risks
  • Bleeding from bite sites, prolonged if early cirrhosis or thrombocytopenia
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Risk in patients with advanced fibrosis or cirrhosis (variceal bleeding)
  • Risk of missed hepatocellular carcinoma screening
  • Substitution for weight loss, which is the proven primary intervention
  • Delay of resmetirom (FDA-approved for MASH F2-F3), GLP-1, or bariatric surgery evaluation
  • Risk of missed alcohol-related liver disease if alcohol intake is underreported
Who should not consider this
  • Patients with advanced fibrosis (F3) or cirrhosis (F4) with esophageal varices
  • Patients with a low platelet count (thrombocytopenia) or impaired blood clotting from liver disease
  • Patients with active hepatocellular carcinoma
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Pregnant patients
  • Patients who have not engaged with weight loss, diet modification, or evidence-based therapy
What to ask your clinician
  • Have I had FibroScan, MRE, or biopsy to stage my fibrosis?
  • Am I a candidate for resmetirom (FDA-approved for MASH with fibrosis F2-F3)?
  • Have I been offered GLP-1 receptor agonists (semaglutide, tirzepatide) for weight loss?
  • Am I a candidate for bariatric surgery?
  • Has hepatocellular carcinoma screening been arranged (if cirrhosis)?
  • What evidence specifically supports leech therapy for NAFLD?
  • What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care
  • Vomiting blood or passing black tarry stools (possible variceal bleeding)
  • New abdominal swelling or jaundice (possible decompensated cirrhosis)
  • New confusion or sleepiness (possible hepatic encephalopathy)
  • Severe abdominal pain with fever (possible spontaneous bacterial peritonitis)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

What this does NOT mean

  • This is NOT FDA-cleared for NAFLD/MASLD.
  • Animal data and the absence of human studies do NOT establish efficacy versus weight loss, resmetirom, GLP-1 receptor agonists, or bariatric surgery.
  • It does NOT substitute for weight loss, which is the most effective intervention for fatty liver.
  • It does NOT replace hepatocellular carcinoma screening in patients with cirrhosis.
  • It does NOT mean leech application is safe in patients with advanced fibrosis or coagulopathy.

Clinical Profile

Category
Gastrointestinal
ICD-10
K76.0, K75.81
Safety tier
High

Evidence Summary

Non-alcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease, MASLD) is managed per AASLD 2023 guidance with weight loss (>=10% for MASH reversal), Mediterranean diet, exercise, glycemic control, statin therapy when indicated, and resmetirom (FDA-approved 2024) for fibrosis F2-F3. No human clinical study of leech therapy for NAFLD/MASLD, controlled or uncontrolled, was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or the Russian-language literature; this is a search result, not proof that none exists. The only direct data are from rodents: hirudotherapy lowered liver enzymes and improved steatosis on histology in 24 rats with diet-induced metabolic syndrome (Bilden et al. 2026), and a leech preparation reduced liver lipid accumulation in hyperlipidemic rats (Wu and Yang 2018). Use is investigational, and the honest evidence grade is D. Any hepatic-decongestion or antiinflammatory rationale for application is theoretical, would be confounded by concurrent lifestyle change, and cannot address fibrosis progression.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Neither Baskova and Isakhanyan nor Michalsen et al. write about fatty liver disease as such; the closest to the topic in Baskova and Isakhanyan is their discussion of liver diseases in general (hepatitis, cirrhosis) and of indicators of fat metabolism[B1][B3].
  • Baskova and Isakhanyan note that there are few studies of hirudotherapy in diseases of the liver and bile ducts[B1].
  • They express their own opinion (“in our view”): since, in their words, leeches can normalize impaired blood coagulation and correct other functional liver disorders, hirudotherapy can be recommended to patients with hepatitis and cirrhosis of the liver; they give no results in such patients in the text[B1].
  • At the same time, Flecken and Michalsen (chapter on contraindications) write that hirudotherapy should never be performed in severe unstable organ disease or marked suppression of the immune system (chemotherapy), while severe chronic but stable organ diseases, such as cirrhosis of the liver, are classed as relative contraindications, with cirrhosis accompanied by a warning about coagulation disorders[B3].
  • Of the observations that Baskova and Isakhanyan give, the closest to the topic of fat metabolism is the one in 20 patients: patients with coronary heart disease, lung diseases and rheumatism are named, and liver diseases are not named among them; according to their data, triglycerides and cholesterol in the blood fell statistically significantly after hirudotherapy compared with before, while total lipids and β-lipoproteins fell non-significantly; the authors themselves write that these observations are not enough to judge a pronounced anti-atherosclerotic effect[B1].
  • Among the contraindications Baskova and Isakhanyan name hemophilia, bleeding disorders (hemorrhagic diatheses), anemia, the use of anticoagulants and simultaneous alcohol consumption[B1].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Cirrhosis (Child-Pugh B/C, or any decompensation)
  • Esophageal varices or portal hypertension
  • Coagulopathy from hepatic dysfunction
  • Concurrent alcoholic or viral hepatitis
  • Hepatocellular carcinoma surveillance abnormality

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.